Search results

The purpose of this study is to establish a synthetic group decision framework based on the Pythagorean fuzzy (PF) set to select the optimal medicine cold chain logistics provider (MCCLP). Fierce market competition makes enterprises must constantly improve every link in the process of enterprise sustainable development. The evaluation of MCCLP in pharmaceutical enterprises is an important link to enhance the comprehensive competitiveness. Because of the fuzziness of expert cognition and the complexity of the decision procedure, PF set can effectively handle the uncertainty and ambiguity in the process of multi-criteria group decision decision-making (MCGDM).

This paper develops an integrated group decision framework through combining the Decision-Making Trial and Evaluation Laboratory (DEMATEL) technique and combined compromise solution (CoCoSo) approach to select a satisfactory MCCLP within PF circumstances. First, the PF set is used to process the ambiguity and uncertainty of the cognition ability of experts. Second, a novel PF knowledge measure is propounded to measure the vagueness of the PF set. Third, a comprehensive criterion weight determination technique is developed through aggregating subjective weights attained utilizing the PF DEMATEL approach and objective weight deduced by knowledge measure method. Furthermore, an integrated MCGDM approach based on synthetic weight and CoCoSo method is constructed.

The outcomes of sensibility analysis and comparison investigation show that the suggested decision framework can help decision experts to choose a satisfactory MCCLP scientifically and reasonably. Accordingly, the propounded comprehensive decision framework can be recommended to enterprises and organizations to assess the MCCLP for their improvement of core competitiveness.

MCCLP selection is not only momentous for pharmaceutical enterprises to improve transportation quality and ensure medicine safety but also provides a strong guarantee for enterprises to improve their core competitiveness. Nevertheless, enterprises face certain challenges due to the uncertainty of the assessment environment as well as human cognition in the process of choosing a satisfactory MCCLP. PF set possesses a formidable capability to address the uncertainty and imprecision information in the process of MCGDM. Therefore, pharmaceutical enterprises can implement the proposed method to evaluate the suppliers to further improve the comprehensive profit of enterprises.

This study examines the impact of environmental, social and governance (ESG) performance on cross-region investment in China.

This study utilized firm-level data from the China Stock Market and Accounting Research database covering 2009 to 2021, comprising 3,600 Chinese listed firms. Cross-region investment activities were measured using data on establishing subsidiaries across regional borders obtained from the TianYanCha website. Besides, this study also implemented the instrumental variables (IV) and difference-in-differences approach to address potential endogeneity issues. The panel Poisson and panel negative binomial models are used for robustness tests.

The findings indicate that companies with better ESG performance are more likely to establish cross-region subsidiaries, positively affecting cross-regional investment activities. Strong ESG performance reduces financing constraints, enhances information transparency and improves corporate reputation and resource allocation efficiency, thereby increasing cross-regional investment. Well-established ESG performance also helps overcome judicial barriers. Moreover, cross-region investments driven by ESG are less motivated by tax avoidance, pollution transfer and management self-interest.

We focus on listed companies in China, which may limit the applicability of our conclusions to other regions. Our measurement of cross-region investment might also underestimate its extent due to diverse investment methods. We suggest two future research directions: first, studies could explore the future performance of ESG-facilitated cross-region investments; second, further analysis could assess whether corporate ESG performance effectively dismantles administrative barriers and mitigates market segmentation.

Under China’s distinctive market segmentation phenomenon, this study fills a gap by providing new causal evidence of the role of managerial performance in mitigating capital flow boundaries.